Table 2.
List of the 26 studies included in this review. All studies had retrospective design
| Ref | First author | Year | Journal | No. of patients | No. of patients in separate validation set | No. of scanner/magnetic fields | MRI sequences | WHO grade glioma |
|---|---|---|---|---|---|---|---|---|
| [32] | Calabrese | 2022 | Neurooncol Adv | 381 | – | 1/3 T | 3D T1, 3D T1-Gd, 3D FLAIR, 3D T2, SWI, ASL, DWI | IV |
| [33] | Chen | 2022 | J Clin Med | 111 | 22 | 1/3 T | T1, T1-Gd, T2, FLAIR | II–IV |
| [34] | Crisi | 2020 | J Neuroimaging | 59 | – | 1/3 T | DSC | IV |
| [35] | Do | 2022 | Sci Rep | 53 | – | TCIA | T1, T1-Gd, T2, FLAIR | IV |
| [36] | Hajianfar | 2019 | World Neurosurg | 82 | – | TCIA | T1-Gd, FLAIR | IV |
| [37] | Haubold | 2021 | Cancers (Basel) | 164 | 33 |
7/1.5 T and 3 T |
T1, T1-Gd, FLAIR | II–IV |
| [38] | Haubold | 2020 | Eur J Nucl Med Mol Imaging | 34 | – | No mention | T1; DWI-b1000; ADC; SWI; MRF; 3D T1-Gd; FLAIR | I–IV |
| [39] | He | 2022 | BMC Med Imaging | 81 | – | 2/3 T | T1, T1-Gd, T2, DWI | I–IV |
| [40] | Huang | 2021 | J Comput Assist Tomogr | 59 | – | 1/3 T | T1, T1-Gd, T2, FLAIR | II–IV |
| [41] | Huang | 2021 | Cancer Sci | 53 | – | 1/3 T | T1, T1-Gd, T2, FLAIR | I–IV |
| [42] | Jiang | 2019 | Eur J Radiol | 122 | 35 | 1/3 T | 3D T1-Gd, T2 | II–III |
| [43] | Kihira | 2021 | Neurooncol Adv | 111 | 20 |
7/1.5 T and 3 T |
3D T1-Gd, 3D FLAIR, DWI | II–IV |
| [44] | Kihira | 2022 | Cancers (Basel) | 208 | 31 | No mention | FLAIR | II–IV |
| [11] | Korfiatis | 2016 | Med Phys | 155 | – |
4/1.5 T and 3 T |
T1, T1-Gd, T2 | IV |
| [14] | Le | 2020 | J Pers Med | 53 | – | TCIA | T1, T1-Gd, T2, FLAIR | IV |
| [12] | Li | 2018 | Eur Radiol | 193 | 60 | 1/3 T | T1, T1-Gd, T2, FLAIR | IV |
| [45] | Lu | 2020 | Magn Reson Imaging | 181 | 54 |
3/1.5 T and 3 T |
T1-Gd | IV |
| [46] | Pasquini | 2021 | Front Oncol | 156 | – |
2/1.5 T and 3 T |
3D T1-Gd, T2, FLAIR, DWI, DSC | IV |
| [53] | Pease | 2022 | J Neurooncol | 114 | 28 | TCIA | T1-Gd, FLAIR | IV |
| [47] | Sasaki | 2019 | Sci Rep | 162 | – |
10/1.5 T and 3 T |
T1, T2, T1-Gd | IV |
| [48] | Shboul | 2020 | Sci Rep | 108 | 27 | TCIA | T1, T1-Gd, T2, FLAIR | II–III |
| [15] | Sohn | 2021 | J Neurooncol | 418 | 126 | 1/3 T | 3D T2, 3D FLAIR, 3D T1-Gd | IV |
| [49] | Verduin | 2021 | Cancers (Basel) | 147 | 43 | Several/1 T–3 T | T1-Gd, T2 | IV |
| [50] | Vils | 2021 | Front Oncol | 118 | 49 | 17/1 T–3 T | T1-Gd | IV |
| [51] | Wei | 2019 | Eur Radiol | 105 | 31 | 1/3 T | T1-Gd, FLAIR, ADC | II–IV |
| [52] | Xi | 2018 | J Magn Reson Imaging | 118 | 20 | 2/3 T | T1, T1-Gd, T2 | IV |
Abbreviations: ADC apparent diffusion coefficient, ASL arterial spin labeling, DWI diffusion-weighted imaging, DSC dynamic susceptibility contrast, MRF magnetic resonance fingerprinting, T1-Gd T1-weighted images after gadolinium injection, TCIA The Cancer Imaging Archive, SWI susceptibility-weighted imaging